NeoVax(MI) vaccine developed by Dana-Farber Cancer Institute could be approved soon with promising results in boosting immune response in melanoma patients
Lara Maior
Health
Vyacheslav Lopatin / Alamy / Profimedia
Always see our news on Google
The clinical trial of the personalized vaccine NeoVax(MI) has shown promising results in the treatment of melanoma, generating a strong immune response. The vaccine contains patient-specific neoantigens and is administered together with standard immunotherapies such as nivolumab and ipilimumab. Scientists observed an increase in immune cells after vaccination, indicating effective immune activation. This innovative approach could significantly improve treatments for skin cancer.
Sources
Vaccinul contra unui tip agresiv de cancer, la un pas de a intra pe piață. Rezultatele remarcabile dau speranțe pacienților
Consiliul Concurenței analizează tranzacţia prin care Mehiläinen Oy preia rețeaua de centre mediale Regina Maria
Consiliul Concurenţei analizează preluarea Grupului Regina Maria de către Mehiläinen Oy
Latest News
18:57
INHGA announces low Danube flows at the point of entry into the country, during September 19–26
18:39
Nicușor Dan, at the Summit of the Romanian Community in Chicago: Romania must acknowledge the unfulfilled promises and regain the trust of Romanians in the diaspora
18:27
Raluca Turcan urges parliamentarians not to reject dialogue in support of a government led by Siegfried Mureșan: “It is imperative that we reach a vote in Parliament”
17:54
CFR SA announced that the international IRN 461 “Romania” train was stranded on the Giurgiu-Ruse bridge after a locomotive problem
17:48
The mayor of Caracal resigns from office after a road accident and brain surgery
See more news
NEWS ON THE SAME TOPICS
.webp)
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
